Dopamine Signals the Value of Delayed Rewards

Reports new study in Biological Psychiatry

Philadelphia, PA, May 11, 2015

Dopamine is the chemical messenger in the brain most closely associated with pleasure and reward. Recent scientific advances now shed light on precise roles for dopamine in the reward process.

A new paper published in the current issue of Biological Psychiatry implicates dopamine in a person’s ability to be motivated by delayed rewards.

People like immediate reinforcement and tend to devalue rewards that are substantially delayed in time. As a result, people will often opt for smaller immediate rewards as opposed to larger delayed rewards when given a choice.

This decision-making process of weighing benefits versus costs for a particular outcome is called “delay discounting”. Though we perform these cost-benefit analyses in a seemingly effortless manner, scientists are still learning how the brain performs these complex processes.

In the current study, researchers at the University of North Carolina at Chapel Hill and Stanford University used rodent models to examine the role of this neurotransmitter in dynamically tracking specific elements of value-based decision making.

First, they trained one set of rats to choose between two different options, a small sweet reward that could be eaten right away, or a bigger sweet reward that was delivered only after varying delays.

Senior author Dr. Regina Carelli explained their findings, “We found that dopamine signaled the more preferred option; more dopamine was observed for cues signaling immediate large rewards, but this declined as the delay to the large reward increased.” This shift in in dopamine release and associated tendency to choose smaller immediate rewards over larger delayed rewards is consistent with the phenomenon of delay discounting.

Next, using a technique known as optogenetics in a second set of rats, they precisely controlled the activity of dopamine neurons during cues that signaled large or delayed rewards. This experiment revealed that, by ‘playing back’ the patterns of dopamine release observed in the first set of rats (when they were pondering which choice to make), the researchers could bias them toward making different decisions in the future.

“These exciting new findings suggest that dopamine plays a sophisticated role in helping to guide specific aspects of decision-making behavior,” Carelli added.

Dr. John Krystal, Editor of Biological Psychiatry, commented, “Delay discounting is an important and poorly understood process. Understanding how it works sheds light on how dopamine signals reward in the brain. It also may help to develop preventive strategies for drug abuse, gambling disorders, and other clinical conditions where delay discounting may play a role.” 

The article is “Mesolimbic Dopamine Dynamically Tracks, and Is Causally Linked to, Discrete Aspects of Value-Based Decision Making” by Michael P. Saddoris, Jonathan A. Sugam, Garret D. Stuber, Ilana B. Witten, Karl Deisseroth, and Regina M. Carelli (doi: 10.1016/j.biopsych.2014.10.024). The article appears in Biological Psychiatry, Volume 77, Issue 10 (May 15, 2015), published by Elsevier.


Notes for editors
Full text of the article is available to credentialed journalists upon request; contact Rhiannon Bugno at +1 214 648 0880 or Journalists wishing to interview the authors may contact Dr. Regina Carelli at +1 919 962 8775 or

The authors’ affiliations, and disclosures of financial and conflicts of interests are available in the article.

John H. Krystal, M.D., is Chairman of the Department of Psychiatry at the Yale University School of Medicine, Chief of Psychiatry at Yale-New Haven Hospital, and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here.

About Biological Psychiatry
Biological Psychiatry is the official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.

The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.

Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 5th out of 135 Psychiatry titles and 14th out of 251 Neurosciences titles in the Journal Citations Reports® published by Thomson Reuters. The 2013 Impact Factor score for Biological Psychiatry is 9.472.

About Elsevier
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.

Media contact
Rhiannon Bugno
Editorial Office, Biological Psychiatry
+1 214 648 0880